on. ALL INVESTORS AND SECURITY HOLDERS OF CEPHALON ARE URGED TO READ ANY SUCH DOCUMENTS FILED WITH THE SEC BY VALEANT CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SUCH TRANSACTION. Investors and security holders will be able to obtain free copies of documents filed with the SEC by Valeant (when they become available) at the web site maintained by the SEC at www.sec.gov
or from Valeant's website (www.valeant.com
) under the tab "Investor Relations" and then under the heading "SEC Filings," or by directing a request to Valeant, One Enterprise, Aliso Viejo, California, 92656, Attention: Corporate Secretary.
CERTAIN INFORMATION CONCERNING POTENTIAL PARTICIPANTS IN A SOLICITATION
Valeant, Mr. J. Michael Pearson, Ms. Laurie W. Little and certain of the other directors, executive officers and employees of Valeant may be deemed to be participants in a solicitation under the rules of the SEC. If any consent solicitation is commenced by Valeant in respect of the election of directors to the Board of Directors of Cephalon, the persons nominated by Valeant for election to the Board of Directors may also be deemed to be participants in such solicitation.
Mr. J. Michael Pearson is the Chairman and Chief Executive Officer of Valeant.
Ms. Laurie W. Little is Vice President, Investor Relations of Valeant.
The principal business address of each of Mr. Pearson and Ms. Little is 14 Main St # 140, Madison, New Jersey 07940-1818.
As of the date hereof, Valeant may be deemed to be the beneficial owner of 1,034,908 shares of the common stock of Cephalon, par value $0.01 per share ("Common Stock"), representing 1.366% of the shares of Common Stock outstanding as of March 14, 2011, according to Cephalon's filing on Schedule 14A on March 25, 2011. In addition, as of the date hereof, Valeant may
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine technology :1
|SOURCE Valeant Pharmaceuticals International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Valeant to Acquire Polish Products2
. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine3
. Valeant and Biovail Announce Results of Special Meetings of Shareholders4
. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 20165
. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA6
. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results7
. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan8
. Valeant Announces Pricing of Senior Notes9
. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman10
. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO11
. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)